Bayhill Therapeutics Inc., a Palo Alto, Calif.-based drug company focused on autoimmune diseases like multiple sclerosis, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol BHTX, with Pacific Growth Equities and Lazard Capital Markets serving as co-lead underwriters.
The company has raised $62.75 million in VC funding, from firms like U.S. Venture Partners (21.38% pre-IPO stake), Morgenthaler Ventures (11.38%), De Novo Ventures (11%), CMEA Ventures (10.46%), Lilly Ventures (9.17%), Latterell Venture Partners (7.32%), Montreux Equity Partners (5.5%), A.M. Pappas Life Science Ventures, Boston Life Science Venture Corp., Grand Cathay Venture Capital Co., PAC-LINK Bio Management Corp., Prudence Venture Investment and Vertical Group. www.bayhilltx.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.